Adicet Bio (NASDAQ:ACET – Get Free Report) will likely be posting its quarterly earnings results before the market opens on Tuesday, March 18th. Analysts expect Adicet Bio to post earnings of ($0.36) per share for the quarter.
Adicet Bio (NASDAQ:ACET – Get Free Report) last announced its earnings results on Thursday, March 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.05. On average, analysts expect Adicet Bio to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Adicet Bio Stock Performance
Shares of NASDAQ:ACET opened at $0.78 on Friday. The stock has a market capitalization of $64.71 million, a price-to-earnings ratio of -0.46 and a beta of 1.97. The stock’s 50-day simple moving average is $0.91 and its two-hundred day simple moving average is $1.13. Adicet Bio has a 52-week low of $0.74 and a 52-week high of $2.43.
Analysts Set New Price Targets
Get Our Latest Analysis on ACET
About Adicet Bio
Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
Featured Stories
- Five stocks we like better than Adicet Bio
- Election Stocks: How Elections Affect the Stock Market
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Overbought Stocks Explained: Should You Trade Them?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Adicet Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adicet Bio and related companies with MarketBeat.com's FREE daily email newsletter.